Pyrazolyl Urea Derivatives for VR1 Receptor Affinity and Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds targeting the subtype 1 vanilloid receptor (VR1/TRPV1) for pain treatment lack optimal affinity, metabolic stability, solubility, and bioavailability, necessitating the development of novel compounds with improved properties.
Innovation Solution
Substituted pyrazolyl-based urea derivatives with specific phenyl moieties and O-containing groups are designed to enhance affinity to VR1/TRPV1 receptors, offering improved potency, solubility, metabolic stability, and reduced interactions with transporter and enzyme molecules, thereby improving oral bioavailability and pharmacokinetic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds with high affinity to VR1/TRPV1 receptors are developed, then pain treatment efficacy is improved, but metabolic stability and solubility deteriorate
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical parameters of the pyrazolyl-based urea derivatives, including substituting different groups at specific positions (R1-R10) to optimize the balance between receptor affinity and metabolic stability. The invention changes molecular parameters such as adding fluorine atoms, modifying alkyl chains, and adjusting aromatic substituents to achieve compounds that maintain high VR1 affinity while improving metabolic stability and solubility profiles.
2Reliability
If compounds with high affinity to VR1/TRPV1 receptors are developed, then pain treatment efficacy is improved, but solubility in aqueous media deteriorates
Solution Approach 1:
The patent improves solubility by changing molecular parameters including introducing polar groups (such as hydroxyl, carboxyl, or amine groups), adding ionizable functional groups to enhance aqueous solubility, and modifying the hydrophobic aromatic regions. Specific embodiments include compounds with carboxylic acid groups, hydroxyl groups, or ionizable amines that improve water solubility while maintaining VR1 receptor affinity through careful positioning and selection of substituents.
3Reliability
If compounds with high affinity to VR1/TRPV1 receptors are developed, then pain treatment efficacy is improved, but oral bioavailability deteriorates due to increased interactions with transporter and enzyme molecules
Solution Approach 1:
The patent optimizes oral bioavailability by changing molecular parameters to reduce interactions with transporters and metabolizing enzymes. This includes adjusting molecular weight, logP values, and hydrogen bonding capacity. The invention specifically designs compounds with reduced basicity (lower pKa values), optimized lipophilicity (logP between 2-5), and specific structural features that minimize P-gp efflux and CYP450 metabolism, thereby improving oral bioavailability while maintaining high VR1 affinity.
Data Source
AI summary
The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives of formula (Q) as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.